Androgen receptors frequently are expressed in breast carcinomas (original) (raw)
Related papers
iranian journal of pathology, 2006
Background and Objective: Since the advent of mammography screening, ductal carcinoma in situ (DCIS) of the breast has been diagnosed increasingly. In contrast to the situation in invasive breast carcinoma, there are only a few reports on androgen receptor (AR) status in DCIS and few reports on estrogen (ER) and progesterone (PR) receptors. Materials and Methods: AR expression was examined in 51 cases of DCIS of the breast and correlated to the degree of differentiation and ER/PR expression status in accordance to immunohistochemical results. Results: AR immunoreactivity was noted in 17 of the cases, whereas the other 34 cases were negative. There was also no significant association between AR expression and the degree of differentiation of DCIS; two of the 11 well-differentiated DCIS cases, nine of the 17 intermediately differentiated cases, and six of the 23 poorly differentiated cases were AR positive (p = 0.091). However, a strong association was shown between the expression of ...
Journal of the Egyptian National Cancer Institute, 2012
Although Breast carcinoma had many targeted biomarkers for its treatment, however, it is a heterogeneous disease with different outcomes and need new markers especially for the triple negative group when estrogen receptor, progesterone receptors and Her2/neu are negative. Androgen receptor is a new target with unclear role. The aim of this study was to examine the prevalence of androgen receptors in invasive breast cancer and tries to elucidate its relation to some well recognized clinicopathological and immunohistochemical markers. One hundred and fifty cases of invasive breast carcinoma were evaluated for type, grade and stage and studied immunohistochemically for estrogen receptor, progesterone receptor, Her2/neu and androgen expression. Androgen receptor expression was correlated with histopathological factors and the three studied markers separately then the studied cases were classified into three groups according to estrogen, progesterone receptor and Her2/neu expression and ...
International Archives of BioMedical and Clinical Research, 2017
Background: Breast cancer is the second most common malignancy in Indian women. Among the members of the steroid receptor superfamily the role of estrogen and progesterone receptors (ER and PR) is well established in breast cancer in predicting the prognosis and management of therapy, however, little is known about the clinical significance of androgen receptor (AR) in breast carcinogenesis. The present study was aimed to evaluate the expression of AR in breast cancer and to elucidate its clinical significance by correlating it with other hormonal receptors and clinical parameters. Methods: It was a prospective study which include 30 patients of histopathologically proven breast cancer admitted to department of surgery at S.N Medical College Agra .Expression of AR, ER, PR, HER2/ neu receptor by immunohistochemistry (IHC) and clinical parameters were studied. Results: AR expression is related to ER(P<0.015), PR(p<0.008) and triple negative breast cancer patients (p <0.008). There is significant correlation between AR and menopausal status(p<0.006) while no significant correlation was found with age and parity. Conclusions: Since there is significant association of AR in triple negative and post-menopausal women so we can say that AR expression possibly help in confirming their predictive role for therapeutic response in breast cancer patients
Journal of Oncology, 2019
Steroid nuclear receptors are known to be involved in the regulation of epithelial-mesenchymal transition process with important roles in invasion and metastasis initiation. Androgen receptor (AR) has been extensively studied, but its role in relation to breast cancer patient prognosis remains to be clarified. AR/ER ratio has been reported to be an unfavorable prognostic marker in early primary breast cancer, but its role in the patients with advanced disease has to be cleared. We retrospectively analyzed ER, PgR, and AR expression on a case series of 159 specimens of primary BC samples by using immunohistochemistry and 89 patients of these had luminal tumors for which AR and ER expression and survival data were available. For twenty-four patients both primary and metastatic tumors were available. A significantly shorter overall survival was observed in primary tumors with AR/PgR ratio ≥ 1.54 (HR = 2.27; 95% CI 1.30-3.97; p = 0.004). Similarly OS was significantly shorter when ER/Pg...
Carcinoma of the breast is the most common malignancy of women globally and the incidence has more risen in recent years. The current study was conducted with the objective of assessing estrogen receptor (ER) and progesterone receptor (PR) reactivity patterns of mammary cancers and to evaluate their association with clinicopathological features. A total of 61 cases of breast carcinoma were examined retrospectively using immunostains for estrogen receptor (ER) and progesterone receptor (PR). Staining pattern and intensity were correlated with histological subtypes and nuclear grades of tumors. The left breast was more commonly involved (57%) and tumor size ranged from 0.5-13.0cm. The predominant morphology was infiltrating ductal carcinoma (85.3%). The majority of the cases presented as grade II (55.3%) lesions with tumor necrosis (70%) and lymph node involvement (71.3%). Positive nuclear staining for ER and PR was observed in 70.5% and 57.5 % of invasive carcinomas, respectively. In ER+ cases, fifty five cases (90%) gave diffuse immunohistochemical reaction for ER; inthe remaining 10%, a focal ER reaction was seen. In PR+ cases, 49 cases (80%) gave diffuse immunohistochemical reaction for PR and Inremaining 20% of PR+ tumors, the reaction was heterogeneous. In ductal infiltrative carcinomas the percentage of cases showed ER+ nuclear labeling is higher than those in cases of infiltrative lobular carcinomas. Assessment of ER and PR as prognostic markers for the clinical management of breast cancer patients is strongly advocated to provide best therapeutic options.
Background. To our knowledge, the hormone receptor status of noncontiguous ductal carcinoma in situ (DCIS) occurring concurrently in ER/PgR-negative invasive cancer has not been studied. The current study was undertaken to investigate the ER/PgR receptor status of DCIS of the breast in patients with ER/PgR-negative invasive breast cancer. Methods. We reviewed the immunohistochemical (IHC) staining for ER and PgR of 187 consecutive cases of ER/PgR-negative invasive breast cancers, collected from 1995 to 2002. To meet the criteria for the study, we evaluated ER/PgR expression of DCIS cancer outside of the invasive breast cancer. Results. A total of 37 cases of DCIS meeting the above criteria were identified. Of these, 16 cases (43.2%) showed positive staining for ER, PgR, or both. Conclusions. In our study of ER/PgR-negative invasive breast cancer we found that in 8% of cases noncontiguous ER/PR-positive DCIS was present. In light of this finding, it may be important for pathologists to evaluate the ER/PgR status of DCIS occurring in the presence of ER/PgR-negative invasive cancer, as this subgroup could be considered for chemoprevention.
Turkish Journal of Pathology, 2016
iNTRoDuCTioN estrogen (eR) and progesterone receptors (PR) are considered to be predictive markers for the patient response to hormonal therapy in breast cancer (1). In addition to its prognostic value, human epidermal growth factor receptor (heR2) is an important predictive marker to predict the patient's response to Trastuzumab in mammary carcinomas. Trastuzumab is a humanized monoclonal antibody used, in combination with other drugs, in the treatment of heR2 positive breast carcinomas (2, 3). The american Society of Clinical Oncology (aSCO) and the College of american Pathologists (CaP) outlined guidelines for testing of heR2, eR and PR with continuous review and updates (1, 4, 5). Currently these guidelines require heR2 testing on metastatic and recurrent breast carcinomas (6, 7). It has been published that approximately 20% of breast cancers are heR2 positive for gene amplification or show protein overexpression by immunohistochemistry (IhC) (8, 9). Therefore, determination of heR2 status is critical for patient care and for prediction of response to Trastuzumab. IhC and Fluorescence in situ hybridization (FISh) are the most commonly used methods for testing the heR2 status (5). FISh analysis may be considered by some superior to that of IhC in predicting response to trastuzumab in patients with mammary carcinoma. This may be related to the strict criteria used as cut off in FISh analysis compared to the subjective analysis with personal variations in evaluating IhC results (10). however, others have reported that IhC is as effective as FISh in predicting the response to treatment (11). The concordance has been found to be high among IhC and FISh in negative (0 and 1+) and positive (3+) cases. Steroid hormone receptors (eR and PR) are prognostic markers that determine to great extent the response to adjuvant hormonal therapy. It is the standard of care to test eR and PR in all cases of invasive breast carcinomas and to test eR in ductal carcinoma in situ (DCIS) (5, 12).
Evaluation of Hormone Receptors Status in Breast Carcinoma
Journal of Shaheed Suhrawardy Medical College, 2019
Background & objective: The importance of establishing hormone receptor status of tumors for the treatment of women with hormone receptor-positive breast cancer is often emphasized. It is critical to evaluate hormone receptor status when considering response to endocrine therapy. The present study was intended to evaluate the usefulness of hormone receptor status in breast carcinoma. Materials & Methods: The present study was conducted in the Department of Pathology, Dhaka Medical College, Dhaka over a period 12 months from July 2009 to June 2010. A total of 30 histopathologically diagnosed cases of breast tumors who were also subjected to immunohistochemical (IHC) test for ER, PR status and HER-2/neu were consecutively included in the study. Patients who have already been treated for malignancy or who had a history of receiving radiotherapy were excluded. Result: Age distributions shows that 40% of the patients were early middle-aged (30-40 years), 30% middle-aged and the rest were either < 30 years or >50 years old. Left breast was involved more often (56.7%) than the right breast (43.3%). The predominant location was upper outer quadrant (43.3%), followed by upper inner quadrant (20%), lower outer quadrant (20%), lower inner quadrant (10%) and central (6.7%). Over half (53.3%) of the tumors were < 5 cm and the rest 5 cm or more. Nearly half (46.7%) of the tumors were moderately differentiated, 36.6% well-differentiated and 16.7% poorly differentiated. In majority (83.3%) of the cases lymph-nodes (axillary lymph nodes) were involved. Based on estrogen and progesterone receptor status, over half (53.3%) of the tumors were ER and PR positive and 40% were Her2/neu overexpressed. Conclusion: The study concluded that half of the Bangladeshi breast cancer patients are ER and PR positive and two in every five cases are Her2/neu overexpressed.